Indeed, treatment with a different inhibitor, sunitinib, led to a reduction in tumor size, stabilization of disease, and improvement in hypertension among SDHB-mutated PHEO/PGL patients [54], warranting further evaluation of this compound. This evidence concerns the gene SDHB and hypertensive disorder.